HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CALM3
calmodulin 3
Chromosome 19 Β· 19q13.32
NCBI Gene: 808Ensembl: ENSG00000143933.20HGNC: HGNC:1442UniProt: B4DJ51
255PubMed Papers
25Diseases
2Drugs
8Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedHub Gene
RESEARCH IMPACT
Trending
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
transmembrane transporter bindingcalcium channel regulator activitycalcium ion bindingprotein bindinglong QT syndrome 14catecholaminergic polymorphic ventricular tachycardia 4cardiovascular diseasebacterial disease
✦AI Summary

CALM3 encodes calmodulin 3, one of three identical calmodulin proteins produced by CALM1, CALM2, and CALM3 genes 1. CALM3 is the most actively transcribed of the three calmodulin genes in certain cell types 1. Calmodulin functions as a calcium-binding protein critical for regulating calcium-dependent signaling pathways, including calcineurin-mediated signaling and calcium channel regulation. CALM3 variants cause calmodulinopathies, a group of inherited arrhythmia syndromes characterized by prolonged QT intervals and life-threatening ventricular arrhythmias 23. CALM3 pathogenic variants are associated with Long QT syndromes 14-16 and catecholaminergic polymorphic ventricular tachycardia types 4 and 6 4. Notably, CALM1, CALM2, and CALM3 mutations cause LQTS with atypical features, including neonatal atrioventricular block, and were classified as having strong or definitive evidence for causality 2. CALM3 also functions as the regulatory Ξ΄ subunit of phosphorylase kinase in glycogen storage diseases type IX 5. Beyond cardiac disease, CALM3 polymorphisms associate with bone mineral density variations in postmenopausal women 6 and may modify hypertrophic and dilated cardiomyopathy phenotypes 7. Emerging therapeutic approaches include antisense oligonucleotides and suppression-replacement gene therapy targeting individual CALM genes 34.

Sources cited
1
CALM3 classified as having strong or definitive evidence for causing LQTS with atypical features including neonatal atrioventricular block
PMID: 31983240
2
CALM3 variants cause calmodulinopathies; ASO-mediated depletion of CALM1 ameliorates disease manifestations while other calmodulin genes preserve function
PMID: 39155863
3
CALM3 encodes the regulatory Ξ΄ subunit of phosphorylase kinase in glycogen storage disease type IX
PMID: 30659246
4
CALM3 pathogenic variants cause Long QT syndrome and catecholaminergic polymorphic ventricular tachycardia; suppression-replacement gene therapy can treat all calmodulinopathies
PMID: 39069900
5
CALM3 is at least 5-fold more actively transcribed than CALM1 or CALM2 in teratoma cells; three CALM genes encode identical calmodulin protein
PMID: 9681195
6
CALM3 polymorphisms significantly associated with femoral neck, hip, and spine bone mineral density in postmenopausal Caucasian women
PMID: 25396734
7
CALM3 polymorphisms associated with increased risk of hypertrophic and dilated cardiomyopathies and may act as disease modifiers
PMID: 28744816
Disease Associationsβ“˜25
long QT syndrome 14Open Targets
0.77Strong
catecholaminergic polymorphic ventricular tachycardia 4Open Targets
0.74Strong
cardiovascular diseaseOpen Targets
0.53Moderate
bacterial diseaseOpen Targets
0.50Moderate
Prolonged QT intervalOpen Targets
0.49Moderate
catecholaminergic polymorphic ventricular tachycardiaOpen Targets
0.47Moderate
Romano-Ward syndromeOpen Targets
0.47Moderate
Abnormality of the cardiovascular systemOpen Targets
0.44Moderate
anthrax infectionOpen Targets
0.37Weak
catecholaminergic polymorphic ventricular tachycardia 1Open Targets
0.34Weak
familial long QT syndromeOpen Targets
0.11Weak
Alzheimer diseaseOpen Targets
0.10Weak
cancerOpen Targets
0.09Suggestive
glioblastoma multiformeOpen Targets
0.09Suggestive
esophageal squamous cell carcinomaOpen Targets
0.09Suggestive
Familial progressive cardiac conduction defectOpen Targets
0.09Suggestive
Miyoshi myopathyOpen Targets
0.09Suggestive
hypertrophic cardiomyopathyOpen Targets
0.08Suggestive
Arrhythmogenic right ventricular dysplasiaOpen Targets
0.08Suggestive
Rare familial disorder with hypertrophic cardiomyopathyOpen Targets
0.08Suggestive
Long QT syndrome 14UniProt
Long QT syndrome 15UniProt
Long QT syndrome 16UniProt
Ventricular tachycardia, catecholaminergic polymorphic, 4UniProt
Ventricular tachycardia, catecholaminergic polymorphic, 6UniProt
Pathogenic Variants8
NM_005184.4(CALM3):c.286G>C (p.Asp96His)Pathogenic
Long QT syndrome 1|Long QT syndrome 16
β˜…β˜…β˜†β˜†2023β†’ Residue 96
NM_005184.4(CALM3):c.421G>A (p.Glu141Lys)Pathogenic
Long QT syndrome 16|Long QT syndrome 1
β˜…β˜…β˜†β˜†2021β†’ Residue 141
NM_005184.4(CALM3):c.426T>G (p.Phe142Leu)Pathogenic
Long QT syndrome 1
β˜…β˜†β˜†β˜†2024β†’ Residue 142
NM_005184.4(CALM3):c.281A>C (p.Asp94Ala)Pathogenic
Long QT syndrome 1|not provided
β˜…β˜†β˜†β˜†2022β†’ Residue 94
NM_005184.4(CALM3):c.390C>G (p.Asp130Glu)Pathogenic
Long QT syndrome 1
β˜…β˜†β˜†β˜†2021β†’ Residue 130
NM_005184.4(CALM3):c.422A>G (p.Glu141Gly)Likely pathogenic
Long QT syndrome 1
β˜…β˜†β˜†β˜†2019β†’ Residue 141
NM_005184.4(CALM3):c.395A>G (p.Asp132Gly)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2017β†’ Residue 132
NM_005184.4(CALM3):c.389A>G (p.Asp130Gly)Pathogenic
Long QT syndrome 16
β˜†β˜†β˜†β˜†2020β†’ Residue 130
View on ClinVar β†—
Drug Targets2
BENZIODARONEApproved
Calmodulin inhibitor
cardiovascular disease
PRENYLAMINEApproved
Sodium channel protein type V alpha subunit blocker
cardiovascular disease
Related Genes
ADCY3Protein interaction100%ADCY9Protein interaction100%CACNA1AProtein interaction100%CACNA1CProtein interaction100%CACNA1DProtein interaction100%CACNA1FProtein interaction100%
Tissue Expression6 tissues
Brain
100%
Heart
30%
Bone Marrow
28%
Lung
14%
Liver
9%
Ovary
8%
Gene Interaction Network
Click a node to explore
CALM3ADCY3ADCY9CACNA1ACACNA1CCACNA1DCACNA1F
PROTEIN STRUCTURE
Preparing viewer…
PDB7BF1 Β· 1.24 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.28Highly Constrained
pLIβ“˜
0.99Intolerant
Observed/Expected LoF0.00 [0.00–0.28]
RankingsWhere CALM3 stands among ~20K protein-coding genes
  • #1,506of 20,598
    Most Researched255 Β· top 10%
  • #545of 1,025
    FDA-Approved Drug Targets2
  • #3,026of 5,498
    Most Pathogenic Variants8
  • #955of 17,882
    Most Constrained (LOEUF)0.28 Β· top 10%
Genes detectedCALM3
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome.
PMID: 31983240
Circulation Β· 2020
1.00
2
Antisense Oligonucleotide Therapy for Calmodulinopathy.
PMID: 39155863
Circulation Β· 2024
0.90
3
Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
PMID: 30659246
Genet Med Β· 2019
0.80
4
Single Construct Suppression and Replacement Gene Therapy for the Treatment of All
PMID: 39069900
Circ Arrhythm Electrophysiol Β· 2024
0.70
5
Localization of the human bona fide calmodulin genes CALM1, CALM2, and CALM3 to chromosomes 14q24-q31, 2p21.1-p21.3, and 19q13.2-q13.3.
PMID: 8314583
Genomics Β· 1993
0.68